11 Dec 2012

Valeritas Raises Record Funding for Central Massachusetts Chapter of American Diabetes Association

Customize font size:

SHREWSBURY, Massachusetts –– [December 11, 2012] – Valeritas announced today that is has raised more than $20,000 as a result of corporate and local fundraising for the Worcester chapter of the American Diabetes Association. Local employees of Valeritas organized a team to generate funding surrounding the Step Out® event. The company then matched the funds raised, reaching a total of $21,978.43. Valeritas, which has manufacturing facilities in Shrewsbury, is known for its leading product, the V-Go, a wearable, disposable device for the delivery of insulin. The proceeds from the fundraising event will benefit the local chapter and be utilized to fund diabetes research, deliver services to hundreds of communities, and raise awareness of the importance of diabetes treatment and prevention.

"Valeritas is incredibly proud to be the top fundraising team and to generate support within this local community for the Central Massachusetts chapter of the American Diabetes Association," said Kristine Peterson, Chief Executive Officer of Valeritas, Inc. "Showing our support is extremely important to us as a company, not only for the diabetes community but also the entire local area where many of our employees live and work at our manufacturing facilities in the heart of central Massachusetts. We are thrilled that these funds can be directly utilized to further support for the diabetes community."

Step Out is a fundraising walk that takes place in 125 cities across the country to raise awareness about diabetes and to raise much needed funds to help change the future of this growing epidemic that is taking a physical, emotional and financial toll on our country. The event is for those who want to become involved in the community and help change the future of diabetes. Participants can walk as an individual or create a team and walk with friends, family, and co-workers.

"We are thrilled that Valeritas is such an actively devoted company, dedicated to improving the lives of people with diabetes," said Christopher Boynton, Executive Director of the American Diabetes Association's Eastern New England region. "Their commitment to developing technologies and patient support programs for people with diabetes is inspiring and will directly help people and communities locally, as well as nationwide."

"As one of the Central Massachusetts ADA Step Out Corporate Co-Chairs, I am incredibly pleased with what our Valeritas colleagues have done to raise diabetes awareness in our area and to be the top local fundraiser to support diabetes research," said Dr. David M. Harlan, Professor of Medicine and Chief, Diabetes Division at the University of Massachusetts School of Medicine.

The American Diabetes Association is leading the fight to Stop Diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

About Diabetes

In order to fuel the human body's cells with glucose, or sugar, insulin is required. While the body continuously produces insulin, people with Type 2 diabetes, the most common form of diabetes, either do not produce enough insulin, or their bodies cannot use the insulin adequately. When there is not enough, or insulin is not used properly, glucose builds up in the blood instead of going into the body's cells. If not controlled properly, diabetes can increase the risk of heart disease, blindness, amputations, stroke, and high blood pressure.

The number of patients diagnosed with diabetes in the United States is alarming and continues to grow. According to the American Diabetes Association, nearly 26 million people in the United States have diabetes,1 with approximately 4.8 million depending on daily insulin injections to help them control and manage their diabetes.2 However, more than half of insulin users do not achieve their recommended target glucose levels for various reasons, including injection pain, or the embarrassment of injecting medication in public.

About the V-Go Disposable Insulin Delivery Device

The V-Go is a simple, fully-disposable device designed and cleared for the delivery of basal-bolus insulin therapy for adults with diabetes. The V-Go delivers a continuous preset basal rate of insulin and allows for on-demand bolus dosing at mealtimes, providing insulin 24 hours per day. Valeritas has received both FDA 510(k) clearance and European CE Mark certification for the V-Go.

Patients fill the V-Go with insulin using a simple, disposable, point-of-care filling accessory — the V-Go EZ Fill (which will be included with each monthly supply of V-Go devices). A separate prescription for insulin is required for use with the V-Go. Humalog® and NovoLog® have both been tested by Valeritas, Inc. and found safe for use with the V-Go.

Important Risk Information: If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Disposable Insulin Delivery Device may result in hypoglycemia. The following conditions may occur during insulin therapy with the V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at the infusion site. The V-Go should be removed before any magnetic resonance imaging (MRI) testing.